Anti-PD1 in the wonder-gut-land
After the initial success of cancer immunotherapy using immune checkpoint blockers,the challenge is to understand why only a minority of patients respond to the therapy and to increase the rate of response.Three recent papers now report that the gut microbiota modulates the response to anti-PD1 therapy in patients with epithelial cancers or melanoma.
28
2021-07-16(万方平台首次上网日期,不代表论文的发表时间)
共2页
263-264